Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Leonetti, Sugandhi Sharma, R. Minari, P. Perego, E. Giovannetti, M. Tiseo (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancerBritish Journal of Cancer, 121
SS Ramalingam, JC-H Yang, CK Lee (2018)
Osimertinib as first-line treatment of EGFR mutation–positive advanced non–small-cell lung cancerJ Clin Oncol, 36
T. Reungwetwattana, K. Nakagawa, B. Cho, M. Cobo, E. Cho, A. Bertolini, S. Bohnet, Caicun Zhou, K. Lee, N. Nogami, I. Okamoto, N. Leighl, R. Hodge, A. McKeown, Andrew Brown, Y. Rukazenkov, S. Ramalingam, J. Vansteenkiste (2018)
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
D. Ettinger, W. Akerley, H. Borghaei, Andrew Chang, R. Cheney, L. Chirieac, T. D’amico, T. Demmy, R. Govindan, F. Grannis, S. Grant, L. Horn, T. Jahan, R. Komaki, F. Kong, M. Kris, L. Krug, R. Lackner, I. Lennes, B. Loo, R. Martins, G. Otterson, J. Patel, M. Pinder-Schenck, K. Pisters, K. Reckamp, Gregory Riely, E. Rohren, T. Shapiro, S. Swanson, K. Tauer, D. Wood, Stephen Yang, K. Gregory, M. Hughes (2013)
Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelinesJournal of The National Comprehensive Cancer Network, 11
W. Zhong, Qun Wang, W. Mao, Songtao Xu, Lin Wu, Yi Shen, Yongyu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, K. Fei, Xiao-fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Ke-Neng Chen, Shi-dong Xu, Lunxu Liu, P. Yu, Buhai Wang, Haining Ma, Hong-Hong Yan, Xue-Ning Yang, Qing Zhou, Yi-long Wu (2018)
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.The Lancet. Oncology, 19 1
J. Cho, S. Lim, H. An, K. Kim, K. Park, E. Kang, Yoon Choi, M. Ahn, M. Lee, Jong-Mu Sun, Se-Hoon Lee, J. Ahn, Keunchil Park, M. Ahn (2019)
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(2020)
Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation-final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial
FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations
(2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Eun Kim, Eun Cho, H. Park, Ji Hong, Seri Lim, J. Youn, S. Hwang, Y. Chang (2016)
Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinomaCancer Biology & Therapy, 17
H. Yu, M. Arcila, M. Hellmann, M. Kris, M. Ladanyi, Gregory Riely (2014)
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.Annals of oncology : official journal of the European Society for Medical Oncology, 25 2
Yujie Dong, Zhen Zhou, Jianguo Wang, Li Ma, Zichen Liu, Yuxuan Wang, Jing Song, Shucai Zhang, N. Che (2019)
Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs.Pathology, research and practice, 215 5
Y. Taniguchi, A. Tamiya, K. Nakahama, Yoko Naoki, M. Kanazu, N. Omachi, K. Okishio, T. Kasai, S. Atagi (2017)
Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors.Oncology letters, 14 6
A. Passaro, T. Mok, S. Peters, S. Popat, M. Ahn, F. Marinis (2020)
Recent Advances on the Role of EGFR TKIs in the Management of NSCLC with Uncommon, non-exon 20 insertion EGFR Mutations.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
D. Datta, B. Lahiri (2003)
Preoperative evaluation of patients undergoing lung resection surgery.Chest, 123 6
T. Mok, Yi-long Wu, M. Ahn, M. Garassino, H. Kim, S. Ramalingam, F. Shepherd, Yong He, H. Akamatsu, W. Theelen, C. Lee, M. Sebastian, A. Templeton, H. Mann, M. Marotti, S. Ghiorghiu, V. Papadimitrakopoulou (2017)
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung CancerThe New England Journal of Medicine, 376
N. Pennell, J. Neal, J. Chaft, C. Azzoli, P. Jänne, R. Govindan, T. Evans, D. Costa, H. Wakelee, R. Heist, M. Shapiro, A. Muzikansky, S. Murthy, M. Lanuti, V. Rusch, M. Kris, L. Sequist (2019)
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37 2
Wei-Yuan Chang, Yi-Lin Wu, P. Su, S. Yang, Chien-Chung Lin, W. Su (2018)
The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasisPLoS ONE, 13
D. Yue, Shidong Xu, Qun Wang, Xiaofei Li, Yi Shen, Heng Zhao, Chun Chen, W. Mao, Wei Liu, Junfeng Liu, Lanjun Zhang, Haitao Ma, Qiang Li, Yue Yang, Yongyu Liu, Haiquan Chen, Changli Wang (2018)
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.The Lancet. Respiratory medicine, 6 11
M. Majem, J. Goldman, T. John, C. Grohé, K. Laktionov, S. Kim, T. Kato, H. Vu, Shun Lu, K. Lee, C. Akewanlop, C. Yu, F. Marinis, L. Bonanno, M. Dómine, F. Shepherd, L. Zeng, D. Kulkarni, N. Medić, M. Tsuboi, R. Herbst, Yi-long Wu (2021)
OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLCJournal of Thoracic Oncology, 16
C. Chouaid, S. Danson, S. Andreas, O. Siakpere, L. Benjamin, R. Ehness, M. Dramard-Goasdoue, J. Barth, H. Hoffmann, V. Potter, F. Barlesi, M. Price, C. Chirila, K. Hollis, C. Sweeney, S. Wolowacz, J. Kaye, I. Kontoudis (2018)
Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.Lung cancer, 124
E. Felip, N. Altorki, Caicun Zhou, T. Csőszi, I. Vynnychenko, O. Goloborodko, A. Luft, A. Akopov, A. Martínez-Martí, H. Kenmotsu, Yuh-Min Chen, A. Chella, S. Sugawara, D. Voong, Fan Wu, J. Yi, Y. Deng, M. McCleland, E. Bennett, B. Gitlitz, H. Wakelee (2021)
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialThe Lancet, 398
Y Taniguchi, A Tamiya, K Nakahama (2017)
Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitorsOncol Lett, 14
D. Planchard (2020)
Adjuvant Osimertinib in EGFR-Mutated Non-Small-Cell Lung Cancer.The New England journal of medicine, 383 18
S. Monica, R. Minari, Daniele Cretella, L. Flammini, C. Fumarola, M. Bonelli, A. Cavazzoni, Graziana Digiacomo, M. Galetti, D. Madeddu, A. Falco, C. Lagrasta, A. Squadrilli, E. Barocelli, A. Romanel, F. Quaini, P. Petronini, M. Tiseo, R. Alfieri (2019)
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLCJournal of Experimental & Clinical Cancer Research : CR, 38
P. Goldstraw, K. Chansky, J. Crowley, R. Rami-Porta, H. Asamura, W. Eberhardt, A. Nicholson, P. Groome, A. Mitchell, V. Bolejack, R. Rami-Porta, D. Ball, D. Beer, R. Beyruti, F. Detterbeck, Wilfried Eberhardt, J. Edwards, F. Galateau-Salle, D. Giroux, F. Gleeson, James Huang, C. Kennedy, Jhingook Kim, Y. Kim, L. Kingsbury, H. Kondo, M. Krasnik, K. Kubota, A. Lerut, G. Lyons, M. Marino, E. Marom, J. Meerbeeck, T. Nakano, A. Nowak, M. Peake, T. Rice, K. Rosenzweig, E. Ruffini, V. Rusch, N. Saijo, P. Schil, J. Sculier, L. Shemanski, K. Stratton, Kenji Suzuki, Y. Tachimori, C. Thomas, W. Travis, M. Tsao, A. Turrisi, J. Vansteenkiste, Hirokazu Watanabe, Yi‐Long Wu, P. Baas, J. Erasmus, S. Hasegawa, K. Inai, K. Kernstine, H. Kindler, L. Krug, K. Nackaerts, H. Pass, D. Rice, C. Falkson, P. Filosso, G. Giaccone, K. Kondo, M. Lucchi, M. Okumura, E. Blackstone, A. Cavaco, A. Barrera, Abal Arca, Parente Lamelas, Arnau Obrer, Guijarro Jorge, D. Ball, G. Bascom, B. Orozco, González Castro, M. Blum, D. Chimondeguy, V. Cvijanović, S. Defranchi, B. Navarro, Escobar Campuzano, Macía Vidueira, F. Araujo, André Garcia, K. Fong, Francisco Corral, C. Gonzalez, Freixinet Gilart, García Arangüena, García Barajas, P. Girard, T. Goksel, González Budiño, González Casaurrán, Gullón Blanco, Hernández Hernández, Hernández Rodríguez, Herrero Collantes, Iglesias Heras, Izquierdo Elena, E. Jakobsen, S. Kostas, León Atance, Núñez Ares, M. Liao, M. Losanovscky, G. Lyons, R. Magaroles, L. Júlvez, Mariñán Gorospe, B. McCaughan, C. Kennedy, M. Íñiguez, Miravet Sorribes, Naranjo Gozalo, Álvarez Arriba, Núñez Delgado, Padilla Alarcón, Peñalver Cuesta, J. Park, H. Pass, Pavón Fernández, M. Rosenberg, E. Ruffini, V. Rusch, Sánchez Escuín, Saura Vinuesa, Serra Mitjans, T. Strand, D. Subotic, S. Swisher, R. Terra, C. Thomas, K. Tournoy, P. Schil, M. Velasquez, Y. Wu, K. Yokoi (2016)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 11
Yi-long Wu, M. Tsuboi, Jie He, T. John, C. Grohé, M. Majem, J. Goldman, K. Laktionov, Sang-We Kim, T. Kato, H. Vu, Shun Lu, K. Lee, C. Akewanlop, Chong-Jen Yu, F. Marinis, L. Bonanno, M. Dómine, F. Shepherd, L. Zeng, R. Hodge, A. Atasoy, Y. Rukazenkov, R. Herbst (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.The New England journal of medicine
Qingyuan Huang, Jinhui Li, Yihua Sun, Rui Wang, Xinghua Cheng, Haiquan Chen (2016)
Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis.Chest, 149 6
Chutong Lin, Fengling Hu, H. Chu, Peng Ren, Shanwu Ma, Jingdi Wang, J. Bai, Xuan Han, Shaohua Ma (2020)
The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysisThoracic Cancer, 12
J. Pignon, H. Tribodet, G. Scagliotti, J. Douillard, F. Shepherd, R. Stephens, A. Dunant, V. Torri, R. Rosell, L. Seymour, S. Spiro, E. Rolland, R. Fossati, D. Aubert, K. Ding, D. Waller, T. Chevalier (2008)
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 21
D. Ettinger, D. Wood, C. Aggarwal, D. Aisner, W. Akerley, J. Bauman, A. Bharat, D. Bruno, Joe Chang, L. Chirieac, T. D’amico, T. Dilling, M. Dobelbower, S. Gettinger, R. Govindan, M. Gubens, M. Hennon, L. Horn, R. Lackner, M. Lanuti, T. Leal, Jules Lin, B. Loo, R. Martins, G. Otterson, S. Patel, K. Reckamp, Gregory Riely, S. Schild, T. Shapiro, J. Stevenson, S. Swanson, K. Tauer, Stephen Yang, K. Gregory, M. Hughes (2019)
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.Journal of the National Comprehensive Cancer Network : JNCCN, 17 12
S. Ramalingam, J. Vansteenkiste, D. Planchard, B. Cho, J. Gray, Y. Ohe, Caicun Zhou, T. Reungwetwattana, Ying Cheng, B. Chewaskulyong, R. Shah, M. Cobo, K. Lee, P. Cheema, M. Tiseo, T. John, Meng-Chih Lin, F. Imamura, T. Kurata, A. Todd, R. Hodge, M. Saggese, Y. Rukazenkov, J. Soria (2019)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.The New England journal of medicine
A. Addeo, G. Banna, A. Friedlaender (2020)
ADAURA: Mature enough for publication, not for prime time.The oncologist
Yi‐Long Wu, T. John, C. Grohé, M. Majem, J. Goldman, Sang-We Kim, T. Kato, K. Laktionov, H. Vu, Zhijie Wang, Shun Lu, K. Lee, C. Akewanlop, Chong-Jen Yu, F. Marinis, L. Bonanno, M. Dómine, F. Shepherd, L. Zeng, A. Atasoy, R. Herbst, M. Tsuboi (2021)
Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
(2020)
Medicines And Healthcare Products Regulatory AgencyDefinitions
M. Tsuboi, Y. Wu, Jie He, T. John, C. Grohé, M. Majem, J. Goldman, K. Laktionov, S. Kim, T. Kato, H. Vu, C. Akewanlop, C. Yu, F. Marinis, M. Dómine, F. Shepherd, C. Yan, A. Atasoy, R. Herbst (2020)
LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrenceAnnals of Oncology, 31
R. Herbst, M. Tsuboi, T. John, C. Grohé, M. Majem, J. Goldman, Sang-We Kim, D. Marmol, Y. Rukazenkov, Yi-long Wu (2020)
Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.Journal of Clinical Oncology, 38
K. Kelly, N. Altorki, W. Eberhardt, M. O'Brien, D. Spigel, L. Crinò, C. Tsai, Joo‐Hang Kim, E. Cho, P. Hoffman, S. Orlov, P. Serwatowski, Jiuzhou Wang, M. Foley, J. Horan, F. Shepherd (2015)
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 34
The introduction of tyrosine kinase inhibitors (TKI) for the treatment of metastatic non-small cell lung cancer (NSCLC) harbouring sensitizing epidermal growth factor receptor (EGFR) gene mutations revolutionized the diagnostic and treatment algorithm of this subset of patients almost two decades ago. Since then, a number of trials have evaluated the role of TKI therapy in early-stage disease, with encouraging disease-free survival (DFS) results but lack of a survival advantage. ADAURA, a phase III trial evaluating 3 years of adjuvant osimertinib versus placebo in patients harbouring EGFR mutations with completely resected stage IB–IIIA NSCLC, recently reported a profound DFS benefit (hazard ratio 0.21), favourable quality of life and reduction in the risk of brain metastases. These results led to osimertinib’s fast track approval by the US Food and Drug Administration, with this drug thus becoming the first EGFR-TKI approved for the treatment of early-stage disease. However, the key endpoint of overall survival remains immature and questions around indication (i.e. stage, need for adjuvant chemotherapy), optimal treatment duration, biomarkers of response and cost-effectiveness remain to be answered. In this article, we critically appraise the findings of ADAURA and discuss future challenges.
Oncology and Therapy – Springer Journals
Published: Jun 1, 2022
Keywords: Non-small cell lung cancer; Adjuvant; Osimertinib; EGFR; Tyrosine kinase inhibitors
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.